Adjuvant therapy with mitomycin C intravesically for superficial bladder cancer.

ABSTRACT

A retrospective study was carried out using the OPD cards of 25 cases (stage A, grade 2) with transitional cell carcinoma (superficial bladder cancer), to determine effects of Mitomycin C on preventing tumor recurrence. Of these patients, 13 had been managed by surgery (TUR/TUF) only (group 1). The remaining 12 cases (group 2) were given Mitomycin C (intravesically) administration at two weeks post surgery (4 cases/group 2 A) and after several tumor recurrence was found in eight cases (group 2 B). The study compared the mean recurrence rate per year of these three groups. The mean recurrence rate per year of group 1, group 2 A and group 2 B was 0.34, 0.68 and 1.22, respectively, and there was no statistical difference between them. The percentage of recurrence in group 1, group 2 A and group 2 B was 61.5, 50 and 75, respectively. In conclusion, Mitomycin C dose not significantly reduce the recurrence of tumors, but if used two weeks after surgery it dose reduce the percentage of recurrence.